Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fcell.2017.00035 http://scihub22266oqcxt.onion/10.3389/fcell.2017.00035 C5386977!5386977 !28443280     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28443280 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Front+Cell+Dev+Biol 2017 ; 5 (ä): 35 Nephropedia Template TP {{tp|p=28443280 |t=2017. In vivo Reprogramming of Cancer Metabolism by MYC |pdf=|usr=}}{{28443280 }} gab.com Text In vivo Reprogramming of Cancer Metabolism by MYC JO: Front Cell Dev Biol http://www.kidney.de/pget.php?&tw=1&pmid=28443280 #FOAvip The past few decades have welcomed tremendous advancements toward understanding the functional significance of altered metabolism during tumorigenesis. However, many conclusions drawn from studies of cancer cells in a dish (i.e., in vitro) have been put into question as multiple lines of evidence have demonstrated that the metabolism of cells can differ significantly from that of primary tumors (in vivo). This realization, along with the need to identify tissue-specific vulnerabilities of driver oncogenes, has led to an increased focus on oncogene-dependent metabolic programming in vivo. The oncogene c-MYC (MYC) is overexpressed in a wide variety of human cancers, and while its ability to alter cellular metabolism is well-established, translating the metabolic requirements, and vulnerabilities of MYC-driven cancers to the clinic has been hindered by disparate findings from in vitro and in vivo models. This review will provide an overview of the in vivo strategies, mechanisms, and conclusions generated thus far by studying MYC's regulation of metabolism in various cancer models. Twit Text FOAVip In vivo Reprogramming of Cancer Metabolism by MYC ????Front Cell Dev Biol http://www.kidney.de/pget.php?&tw=1&pmid=28443280 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28443280 #FOAvip English Wikipedia <ref>{{Cite pmid|28443280 }}</ref> In vivo Reprogramming of Cancer Metabolism by MYC #MMPMID28443280 Camarda R ; Williams J ; Goga A Front Cell Dev Biol 2017[]; 5 (ä): 35 PMID28443280 show ga The past few decades have welcomed tremendous advancements toward understanding the functional significance of altered metabolism during tumorigenesis. However, many conclusions drawn from studies of cancer cells in a dish (i.e., in vitro) have been put into question as multiple lines of evidence have demonstrated that the metabolism of cells can differ significantly from that of primary tumors (in vivo). This realization, along with the need to identify tissue-specific vulnerabilities of driver oncogenes, has led to an increased focus on oncogene-dependent metabolic programming in vivo. The oncogene c-MYC (MYC) is overexpressed in a wide variety of human cancers, and while its ability to alter cellular metabolism is well-established, translating the metabolic requirements, and vulnerabilities of MYC-driven cancers to the clinic has been hindered by disparate findings from in vitro and in vivo models. This review will provide an overview of the in vivo strategies, mechanisms, and conclusions generated thus far by studying MYC's regulation of metabolism in various cancer models. äIn vivo Reprogramming of Cancer Metabolism by MYC (epmc).pdf DeepDyve Pubget Overpricing